Does Rallies show 13F holders for ALGS?

Yes. Rallies tracks hedge fund and 13F ownership data for ALGS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ALGS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALGS. It does not provide personalized investment advice.

ALGS (Aligos Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Aligos Therapeutics, Inc. Common Stock (ALGS) is a publicly traded Healthcare sector company. As of May 21, 2026, ALGS trades at $5.68 with a market cap of $33.17M and a P/E ratio of -0.63. ALGS moved +8.11% today. Year to date, ALGS is -33.41%; over the trailing twelve months it is -7.59%. Its 52-week range spans $3.76 to $46.80. Analyst consensus is strong buy with an average price target of $73.25. Rallies surfaces ALGS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ALGS stock?

Hedge funds tracked by Rallies that own ALGS include Citadel Advisors, Two Sigma, and Renaissance Technologies. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aligos Therapeutics, Inc. Common Stock.

ALGS Key Metrics

Key financial metrics for ALGS
Metric	Value
Price	$5.68
Market Cap	$33.17M
P/E Ratio	-0.63
EPS	$-8.79
Dividend Yield	0.00%
52-Week High	$46.80
52-Week Low	$3.76
Volume	1.18K
Avg Volume	0
Revenue (TTM)	$4.71M
Net Income	$-90.32M
Gross Margin	0.00%

Top Hedge Funds Holding ALGS

Citadel Advisors holds 277.36K shares of ALGS, changed -2.91% as of Jun 30, 2024.
Two Sigma holds 18.71K shares of ALGS, changed +0.44% as of Jun 30, 2024.
Renaissance Technologies holds 11.44K shares of ALGS, changed -14.88% as of Dec 31, 2024.

Latest ALGS News

Aligos inks Greater China HBV drug deal with $25m upfront, $420m potential — Apr 17, 2026
Aligos Therapeutics Raises Phase 2 HBV Trial Sample to 100, Gains FDA Fast Track — Apr 14, 2026
Aligos Reports High Viral Suppression in Phase 1 HBV Study and Impairment PK Data — Feb 23, 2026

Recent ALGS Insider Trades

Nuechterlein Carole bought 7.93M (~$6.00M) on Oct 25, 2023.

ALGS Analyst Consensus

4 analysts cover ALGS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $73.25.

Common questions about ALGS

Who owns ALGS stock?: Hedge funds tracked by Rallies that own ALGS include Citadel Advisors, Two Sigma, and Renaissance Technologies. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aligos Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ALGS?: Yes. Rallies tracks hedge fund and 13F ownership data for ALGS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ALGS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALGS. It does not provide personalized investment advice.